Polyrizon Overview
Polyrizon is a biotech company focused on the development and commercialization of innovative intranasal products. Polyrizons Capture & Contain (C&C) platform is based on a natural 3D polymeric network tailored to optimally adhere to the nasal mucosal surface. The polymeric network creates a physical barrier that captures and contains biological contaminants, preventing their penetration. The C&C platform can be readily adapted for a wide range of applications to protect the human body from airborne contaminants such as allergens, viruses, and molds. The companys Trap & Target (T&T) platform delivery technology is designed to allow a long residence time and intimate contact with the mucosal tissue for highly effective targeted delivery of medicines. It can be tailored to address the specific requirements of different molecules for improved therapeutic effect.
Cumulative Funding Raised Over Time ($)
$780KAug 2021
$960KJan 2023
$1.4MJun 2023
$1.5MMar 2020
$18.5MMar 2025
$19.2MMay 2022
$19.3MNov 2020
Latest News
growth-positive
Polyrizon Announces Positive Pre-Clinical Results: PL-14 Demonstrates Encouraging Allergen-Blocking Efficacy
Polyrizon Ltd., a biotechnology company, announced promising results from a pre-clinical study of its PL-14 Allergy Blocker formulation. The study demonstrated the formulations ability to effectively limit allergen penetration, forming a nasal barrier against allergens like the house dust mite allergen Der p 1. The results suggest that PL-14 could offer robust protection even under extreme allergen conditions. The company plans to advance its preclinical development program and initiate clinical studies to support regulatory pathways for PL-14 and other candidates within its Capture & Contain platform. The Allergy Immunotherapy market is expected to grow significantly, driven by the increasing prevalence of allergies and advancements in treatment methodologies.
Product Stage
growth-positive
Polyrizon Submits Pre-Sub Package to the FDA for PL-14 Allergy Blocker
Polyrizon Ltd., a biotechnology company, announced the submission of its Pre-Submission package to the FDA for its PL-14 Allergy Blocker, a novel intranasal product designed to alleviate symptoms of allergic rhinitis. This submission marks a significant step in Polyrizons regulatory strategy, potentially leading to marketing clearance. The PL-14 Allergy Blocker aims to provide rapid and long-lasting relief from nasal allergies by forming a physical barrier against allergens. Polyrizons innovative approach, utilizing its proprietary Capture and Contain hydrogel technology, positions the company for accelerated development in the allergy treatment market.
Product Stage
growth-positive
Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study
Polyrizon Ltd., a biotechnology company, announced promising preclinical results for its PL-14 Allergy Blocker, part of its Capture & Contain platform. The study, conducted with the University of Parma, showed that PL-14 achieved over 60% deposition in the nasal vestibule, crucial for blocking allergens. This reinforces its potential as a barrier-forming treatment for allergic rhinitis. The global allergen blocker market is projected to grow, driven by rising allergy incidence and demand for relief products. The results support PL-14s potential as a frontline preventive treatment, with practical self-administration features.
Product Stage
growth-positive
Polyrizon Regains Compliance with Nasdaq Listing Requirements
Polyrizon Ltd., a biotechnology company specializing in intranasal products, has regained compliance with Nasdaq listing requirements. The company received confirmation from the Nasdaq Hearings Panel that it meets the minimum bid price requirement, allowing it to continue trading on the Nasdaq Capital Market under the ticker symbol PLRZ. Polyrizon is in the development stage, focusing on innovative medical device hydrogels delivered as nasal sprays, which act as a barrier against viruses and allergens. Their proprietary Capture and Contain (C&C) hydrogel technology is in pre-clinical development, with further advancements in bioadhesion and drug delivery. The companys compliance with Nasdaq rules is a positive development, ensuring its continued presence in the public market.
growth-positive
Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study
Polyrizon Ltd., a biotechnology company, announced promising preclinical results for its PL-14 Allergy Blocker, part of its Capture & Contain platform. The study, conducted with the University of Parma, showed over 60% deposition in the nasal vestibule, crucial for blocking allergens. This supports PL-14s potential as a barrier-forming treatment for allergic rhinitis. The global allergen blocker market is expected to grow, driven by rising allergy incidences and demand for relief products. PL-14s formulation demonstrated practicality for self-administration, highlighting its potential as a frontline preventive treatment.
Product Stage
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $23.53M |
| Last funding | $17M |
| Stage | Public |
| Rounds | 8 |
| Investors | 2 |
Team Members
4
Employees: 1-10
Web & Social Links
| Website | polyrizon-biotech.com/ |
| Careers | Careers page |
Locations
HaTidhar St 5, Ra'anana, Israel
Photos & Videos
2 item(s)
Polyrizon Business
Business models
B2B2C
Product stage
R&D
Employees
1-10
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrug DeliveryTarget Customer
Healthcare & Life SciencesMedical Devices IndustryMedical ProductsHealthcareProvidersPatientsLife SciencesPharmaceuticalsCore Technology
—Tags (8)
allergybiopharmaceuticalbiotechnologypharmaceuticalsbiomaterialspolymerstopical-treatmentpharma-companiesPolyrizon Financials
$23.53M
Total funding
Undisclosed
Capital raised
$17M
Last funding
Public
Funding stage
8
Total rounds
2
Investors
Cumulative Funding Raised Over Time ($)
$780KAug 2021
$960KJan 2023
$1.4MJun 2023
$1.5MMar 2020
$18.5MMar 2025
$19.2MMay 2022
$19.3MNov 2020
Private Equity Funding
PIPE
Mar 2025
$17M
Seed
Jun 2023
$400K
srugo Reuven construction co. ltd., Xylo Technologies
Seed
Jan 2023
$180K
Xylo Technologies, srugo Reuven construction co. ltd.
Seed
May 2022
$718K
srugo Reuven construction co. ltd., Xylo Technologies
Seed
Aug 2021
$780K
Xylo Technologies, srugo Reuven construction co. ltd.
Undisclosed Round
Nov 2020
$150K
Xylo Technologies, srugo Reuven construction co. ltd.
Undisclosed Round
Mar 2020
$100K
Xylo Technologies
Public Offering / Exit
POEvent
Oct 2024
Undisclosed
Polyrizon Lifecycle
Cumulative Funding Raised Over Time
$780KAug 2021
$960KJan 2023
$1.4MJun 2023
$1.5MMar 2020
$18.5MMar 2025
$19.2MMay 2022
$19.3MNov 2020
All Events
PIPE
Mar 2025
$17M
Seed
Jun 2023
$400K
srugo Reuven construction co. ltd., Xylo Technologies
Seed
Jan 2023
$180K
Xylo Technologies, srugo Reuven construction co. ltd.
Seed
May 2022
$718K
srugo Reuven construction co. ltd., Xylo Technologies
Seed
Aug 2021
$780K
Xylo Technologies, srugo Reuven construction co. ltd.
Undisclosed Round
Nov 2020
$150K
Xylo Technologies, srugo Reuven construction co. ltd.
Undisclosed Round
Mar 2020
$100K
Xylo Technologies
POEvent
Oct 2024
Undisclosed
Polyrizon News
45 articles
growth-positive
Polyrizon Announces Positive Pre-Clinical Results: PL-14 Demonstrates Encouraging Allergen-Blocking Efficacy
Polyrizon Ltd., a biotechnology company, announced promising results from a pre-clinical study of its PL-14 Allergy Blocker formulation. The study demonstrated the formulations ability to effectively limit allergen penetration, forming a nasal barrier against allergens like the house dust mite allergen Der p 1. The results suggest that PL-14 could offer robust protection even under extreme allergen conditions. The company plans to advance its preclinical development program and initiate clinical studies to support regulatory pathways for PL-14 and other candidates within its Capture & Contain platform. The Allergy Immunotherapy market is expected to grow significantly, driven by the increasing prevalence of allergies and advancements in treatment methodologies.
Product Stage
growth-positive
Polyrizon Submits Pre-Sub Package to the FDA for PL-14 Allergy Blocker
Polyrizon Ltd., a biotechnology company, announced the submission of its Pre-Submission package to the FDA for its PL-14 Allergy Blocker, a novel intranasal product designed to alleviate symptoms of allergic rhinitis. This submission marks a significant step in Polyrizons regulatory strategy, potentially leading to marketing clearance. The PL-14 Allergy Blocker aims to provide rapid and long-lasting relief from nasal allergies by forming a physical barrier against allergens. Polyrizons innovative approach, utilizing its proprietary Capture and Contain hydrogel technology, positions the company for accelerated development in the allergy treatment market.
Product Stage
growth-positive
Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study
Polyrizon Ltd., a biotechnology company, announced promising preclinical results for its PL-14 Allergy Blocker, part of its Capture & Contain platform. The study, conducted with the University of Parma, showed that PL-14 achieved over 60% deposition in the nasal vestibule, crucial for blocking allergens. This reinforces its potential as a barrier-forming treatment for allergic rhinitis. The global allergen blocker market is projected to grow, driven by rising allergy incidence and demand for relief products. The results support PL-14s potential as a frontline preventive treatment, with practical self-administration features.
Product Stage
growth-positive
Polyrizon Regains Compliance with Nasdaq Listing Requirements
Polyrizon Ltd., a biotechnology company specializing in intranasal products, has regained compliance with Nasdaq listing requirements. The company received confirmation from the Nasdaq Hearings Panel that it meets the minimum bid price requirement, allowing it to continue trading on the Nasdaq Capital Market under the ticker symbol PLRZ. Polyrizon is in the development stage, focusing on innovative medical device hydrogels delivered as nasal sprays, which act as a barrier against viruses and allergens. Their proprietary Capture and Contain (C&C) hydrogel technology is in pre-clinical development, with further advancements in bioadhesion and drug delivery. The companys compliance with Nasdaq rules is a positive development, ensuring its continued presence in the public market.
growth-positive
Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study
Polyrizon Ltd., a biotechnology company, announced promising preclinical results for its PL-14 Allergy Blocker, part of its Capture & Contain platform. The study, conducted with the University of Parma, showed over 60% deposition in the nasal vestibule, crucial for blocking allergens. This supports PL-14s potential as a barrier-forming treatment for allergic rhinitis. The global allergen blocker market is expected to grow, driven by rising allergy incidences and demand for relief products. PL-14s formulation demonstrated practicality for self-administration, highlighting its potential as a frontline preventive treatment.
Product Stage
growth-negative
BC-Most Active Stocks
The article provides a list of the most active stocks on the Nasdaq, NYSE, and NYSE American exchanges, detailing the volume, high, low, last price, and change for each stock. Opendoor Technologies Inc. is highlighted as the most active stock on the Nasdaq with a significant volume of over 1 billion shares traded. However, its stock price decreased by $0.33, indicating a growth-negative impact. The article does not mention any specific events or issues related to Opendoor Technologies Inc., such as partnerships, investments, or acquisitions. The focus is primarily on stock performance and trading activity.
growth-positive
Polyrizon Retains Nasdaq Listing Following Hearings Panel
Polyrizon Ltd., a development-stage biotech company, has successfully secured the continued listing of its securities on the Nasdaq Capital Market. The company had previously faced a public interest determination from Nasdaq due to its issuance of securities in a private placement. Following a hearing, Polyrizon presented a plan to address Nasdaqs concerns, including simplifying its capital structure and committing to avoid complex financing instruments. The Nasdaq Hearings Panel granted the companys request for continued listing, contingent on compliance with the Minimum Bid Price Rule by October 17, 2025. Polyrizons CEO, Tomer Izraeli, expressed satisfaction with the decision and highlighted the companys efforts to enhance shareholder value and ensure compliance with Nasdaq standards.
PIPE/PO
growth-positive
Polyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS Therapeutics
Polyrizon Ltd., a biotechnology company, announced promising preclinical results for its hydrogel-based Trap & Target (T&T) platform, which is designed for intranasal drug delivery. The study, conducted in collaboration with the University of Parma, demonstrated effective targeted deposition in the nasal cavity, crucial for central nervous system drug delivery. This technology shows potential for treating conditions like opioid overdose and epileptic seizures by providing rapid brain access. The results validate the T&T technologys capabilities and support further preclinical development. Polyrizon plans to continue validating these findings in animal models and initiate safety studies as part of its development roadmap.
Product Stage
growth-negative
Polyrizon Announces Receipt of Nasdaq Delisting Notice
Polyrizon Ltd., a development stage biotech company specializing in innovative intranasal hydrogels, has received a notification from Nasdaq regarding potential delisting due to public interest concerns. The issue stems from a securities issuance that caused significant shareholder dilution. The company plans to request a hearing to stay the delisting process. Polyrizons technology, including Capture and Contain (C&C) and Trap and Target (T&T), is in the development stage, focusing on nasal delivery systems. The companys shares remain listed on Nasdaq under the symbol PLRZ pending the outcome of the hearing.
Public Trading
growth-positive
Polyrizon Emerges with Positive Preclinical Data on Nasal Protection Platform
Polyrizon Ltd., a development stage biotech company, announced promising results from ex vivo studies on its innovative intranasal hydrogel formulation. Conducted in collaboration with Prof. Fabio Sonvicos laboratory, the studies demonstrated strong mucoadhesion and broad surface coverage on nasal tissues, essential for effective intranasal therapeutic delivery. The formulation rapidly spreads and adheres to nasal mucosa, maintaining prolonged retention even under physiological conditions. This enhances its potential for therapeutic efficacy by ensuring the formulation stays in place long enough to exert its intended effect. Polyrizons technology, in pre-clinical development, aims to provide a barrier against viruses and allergens and is being further developed for drug delivery.
Product Stage
growth-positive
Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue Treatment
Polyrizon Ltd., a development stage biotech company, has initiated preclinical studies for intranasal Benzodiazepines (BZDs) as a treatment for acute repetitive seizures and status epilepticus. This marks a significant step in evaluating their Trap and Target™ platform for intranasal drug delivery. The studies are conducted in collaboration with Professor Fabio Sonvico from the University of Parma. The intranasal delivery method offers advantages such as ease of use and accessibility, allowing rapid administration in emergency situations. Polyrizons CEO, Tomer Izraeli, emphasizes the potential of their platform to provide faster and safer seizure management outside clinical settings. The company specializes in innovative intranasal hydrogels, aiming to improve emergency treatment options for epilepsy patients.
Product Stage
growth-positive
Top Midday Gainers
Smart Digital Group (SDM) announced the pricing of its initial public offering (IPO) of 1.5 million shares. This move is seen as growth-positive for the company as it enters the public trading market, potentially increasing its capital and market visibility. The article highlights the companys IPO as a significant event, contributing to its stock performance and positioning on Wall Street. The news is part of a premium newsfeed service that provides broker-level insights, emphasizing the importance of staying informed about market movements and company developments.
Public Trading
growth-positive
Polyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue Model
Polyrizon Ltd., a biotech company specializing in intranasal hydrogels, announced successful preliminary safety results for its PL-14 Allergy Blocker. The study, conducted on human nasal tissue, showed strong local tolerability, marking a significant step in the products development. The PL-14 nasal gel spray acts as a barrier against airborne allergens and demonstrated no inflammatory activation or functional impairment in the study. These findings support Polyrizons regulatory strategy and upcoming FDA pre-submission meeting, paving the way for clinical trials in the U.S. and Europe expected to begin in late 2025 or early 2026. Polyrizons technology aims to provide a drug-free, well-tolerated nasal spray for daily protection against allergens.
Product StageFDA approved/pending approval
growth-negative
Polyrizon Receives Nasdaq Notification Regarding Minimum Bid Requirements
Polyrizon Ltd., a development stage biotech company, has received a notice from Nasdaq indicating non-compliance with the minimum bid price requirement, as its shares have been trading below $1.00 for 30 consecutive days. The company has been granted a 180-day compliance period, until October 6, 2025, to regain compliance by having its share price meet or exceed $1.00 for at least 10 consecutive days. If Polyrizon fails to comply, it may receive an additional 180-day period, provided it meets other listing requirements. The company is exploring options to resolve this issue. Polyrizon specializes in developing intranasal hydrogels that act as a barrier against viruses and allergens.
growth-positive
Polyrizon Engages Leading Branding Firm for Strategic Brand Development
Polyrizon Ltd., a biotech company specializing in intranasal hydrogels, has announced a partnership with a globally recognized branding and trademark consultancy firm. This collaboration aims to develop a strategic brand name and identity for Polyrizons Capture and Contain™ (C&C) hydrogel technology, which is designed to create a protective barrier against allergens and viruses. The initiative is a significant step towards commercializing their technology and ensuring compliance with global regulatory requirements. The brand development process will align with Polyrizons ongoing clinical and regulatory milestones. The company is currently in the development stage, focusing on innovative medical device hydrogels delivered as nasal sprays.
PartnersProduct Stage
growth-positive
Polyrizon Ltd. Announces Closing of $17.0 Million Private Placement
Polyrizon Ltd., a biotech company specializing in intranasal hydrogels, announced the closing of a private placement worth approximately $17 million. The offering included the sale of 35,416,667 Ordinary Units, each comprising one Ordinary Share or Pre-Funded Warrant and one Series A Warrant. The proceeds will be used for general corporate purposes and working capital. Aegis Capital Corp. acted as the exclusive placement agent, with legal counsel from Greenberg Traurig, P.A. and Kaufman & Canoles, P.C. The securities were sold to accredited investors and are subject to certain resale restrictions under the Securities Act.
Investment
growth-positive
Polyrizon Ltd. Announces $17.0 Million Private Placement
Polyrizon Ltd., a biotech company specializing in intranasal hydrogels, announced a private placement with institutional investors, raising approximately $17 million. The offering includes Ordinary Shares and warrants, with Aegis Capital Corp. acting as the exclusive placement agent. The transaction is expected to close by April 1, 2025, and the proceeds will be used for general corporate purposes and working capital. The securities are sold in a private placement and are not registered under the Securities Act. The company has agreed to file registration statements for the resale of the shares and warrants.
Investment
growth-positive
Polyrizon Structures Clinical Strategy for its Allergy Blocker Ahead of FDA Pre-Submission Meeting
Polyrizon Ltd., a biotech company specializing in intranasal hydrogels, is preparing for clinical trials of its allergy blocker, PL-14. The company has updated its clinical strategy in anticipation of a pre-submission meeting with the FDA. The trials will assess the efficacy, safety, and user experience of PL-14, with studies planned in the U.S. and Europe by late 2025 to early 2026. Polyrizon aims to advance PL-14 toward regulatory approval and commercialization, providing value to those suffering from allergic rhinitis. The company is also developing its C&C hydrogel technology for drug delivery.
Product Stage
growth-positive
Polyrizon Expands Drug Delivery Innovation with Preclinical Studies for Epilepsy Rescue Treatment
Polyrizon Ltd., a biotech company specializing in intranasal hydrogels, has initiated preclinical studies for intranasal Benzodiazepines (BZDs) as a treatment for acute repetitive seizures and status epilepticus. This development leverages Polyrizons proprietary drug delivery platform, Trap and Target™ (T&T), to provide rapid and patient-friendly seizure rescue therapy. The studies, conducted in collaboration with Professor Fabio Sonvico from the University of Parma, will evaluate key parameters such as drug loading capacity and nasal deposition. This marks a significant step in advancing Polyrizons platform, aiming to improve the accessibility and effectiveness of seizure treatments.
Product StagePartners
growth-negative
Psychedelic: atai Life Sciences, NRx report quarterly results
The article discusses recent developments in psychedelic stocks, focusing on atai Life Sciences and NRx Pharmaceuticals. atai Life Sciences reported a fourth-quarter loss, with cash reserves significantly reduced compared to the previous year. However, a recent equity offering raised $59.2M, extending their financial runway into 2027. The company is focused on advancing its Phase 2 clinical trials for VLS-01 and EMP-01, with results expected in 2026. NRx Pharmaceuticals also reported a loss but highlighted strategic advancements, including a New Drug Application for NRX-100 and progress towards accelerated approval for NRX-101. Both companies are making strides in mental health treatments, despite financial challenges.
InvestmentProduct Stage
growth-positive
Clearmind to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination
Clearmind Medicine Inc., a clinical-stage biotech company, has signed a non-binding Letter of Intent with Polyrizon Ltd. to develop a novel intranasal formulation for its psychedelic-based treatments. The collaboration aims to enhance the bioavailability and therapeutic effect of Clearminds drug candidate, 5-Methoxy-2-aminoindane (MEAI), potentially in combination with Palmitoylethanolamide (PEA). The initiative will explore the feasibility of intranasal drug delivery, which could offer advantages such as faster absorption and increased patient compliance. Clearmind will fund the research and development process, while Polyrizon will advance formulation development. If successful, a definitive agreement will be negotiated.
PartnersProduct Stage
growth-positive
Polyrizon Signs Non– Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments
Polyrizon Ltd., a development stage biotech company, has signed a non-binding Letter of Intent with a biotech company focused on psychedelic-derived therapeutics. The collaboration aims to develop a novel intranasal formulation for psychedelic-based treatment applications, leveraging Polyrizons proprietary platform to enhance drug delivery. This partnership highlights the potential of intranasal drug delivery in the psychedelic medicine space, aiming to improve bioavailability, efficacy, and patient accessibility. The psychedelic company will fund the research and development process, and Polyrizon will receive royalty payments for any future commercialization. The agreement could lead to further clinical development and commercialization, emphasizing the innovative approach of Polyrizons technology.
Partners
growth-positive
Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform
Polyrizon Ltd., a development stage biotech company, has initiated preclinical studies for its intranasal Naloxone, a treatment for opioid overdose. The study is in collaboration with Professor Fabio Sonvico from the University of Parma. This research aims to evaluate Polyrizons Trap and Target™ platform for Naloxone administration, focusing on drug loading capacity, release kinetics, nasal deposition, and stability. The opioid crisis, exacerbated by synthetic opioids like fentanyl, underscores the need for effective Naloxone delivery. Polyrizons platform could enhance Naloxones bioavailability and effectiveness, offering a critical solution in emergency overdose situations. The global Naloxone market is projected to grow significantly, highlighting the potential impact of Polyrizons innovations.
Product Stage
growth-positive
Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024
Polyrizon Ltd., a development stage biotech company based in Raanana, Israel, has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2024, with the U.S. Securities and Exchange Commission. The company specializes in innovative intranasal hydrogels designed to act as a barrier against viruses and allergens. Their proprietary Capture and Contain (C&C) hydrogel technology is delivered via nasal sprays and is being further developed for enhanced bioadhesion and retention. Additionally, Polyrizon is working on a pre-clinical technology called Trap and Target (T&T) for nasal delivery of active pharmaceutical ingredients. The filing of the annual report is a positive step in the companys growth trajectory.
Product Stage
growth-positive
Polyrizon Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&T Platform
Polyrizon Ltd., a biotech company, has announced the initiation of preclinical studies for its intranasal Naloxone, a treatment for opioid overdose. The studies, conducted in collaboration with Professor Fabio Sonvico from the University of Parma, aim to evaluate Polyrizon’s Trap and Target™ (T&T) platform. This platform is designed to enhance drug delivery, offering higher bioavailability and optimized release profiles for rapid opioid reversal. The opioid crisis, exacerbated by synthetic opioids like fentanyl, has increased the demand for effective treatments like Naloxone. The global market for Naloxone is projected to grow significantly, highlighting the potential impact of Polyrizons innovative approach.
Product Stage
growth-positive
Polyrizon Announces Filing of Divisional Patent Application for Its Innovative Trap & Target™ (T&T) Intranasal Drug Delivery Platform
Polyrizon Ltd., a development-stage biotech company, announced the filing of a divisional patent application with the Israel Patent Office for its Trap & Target (T&T) platform technology. This technology is designed to enhance intranasal drug delivery by increasing drug residence time and improving bioavailability. The patent filing aligns with a recent U.S. application covering Polyrizons core technologies, including Capture and Contain and Trap and Target. The T&T platform aims to revolutionize respiratory health and drug delivery by offering prolonged residence time, improved bioavailability, controlled release, prevention of dripping, and compatibility with various drug types. CEO Tomer Izraeli emphasized the importance of this step in strengthening their intellectual property portfolio and advancing healthcare solutions.
Product Stage
growth-positive
Polyrizon Commences GMP Manufacturing Preliminary Process for its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial
Polyrizon Ltd., a development stage biotech company, has initiated preliminary work on the GMP manufacturing process for its PL-14 allergy blocker, in preparation for a planned 2025 clinical trial. The company has partnered with Eurofins CDMO Amatsiaquitaine S.A.S. to ensure high-quality production and compliance with regulatory standards. The trial will assess the safety and efficacy of PL-14, an innovative intranasal hydrogel designed to block allergies. With the global nasal spray market expected to grow significantly, Polyrizon aims to address allergy-related health challenges with its proprietary nasal spray solutions.
Product StagePartners
growth-positive
Polyrizon Announces Publication of U.S. National Patent Application for Its Innovative Hydrogel Nasal Technologies
Polyrizon Ltd., a development-stage biotech company, announced the publication of a national phase patent application by the USPTO. The patent covers Polyrizons core platform technologies: Capture and Contain (C&C™) and Trap and Target (T&T™). The C&C platform is a nasal blocker technology that forms a barrier to protect against airborne threats, while the T&T platform is a drug delivery system designed for effective medication delivery. These technologies highlight Polyrizons commitment to innovative solutions in nasal protection and drug delivery. The announcement is a positive development for the company, indicating progress in its technological advancements.
growth-positive
Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs
Polyrizon Ltd., a biotech company specializing in intranasal hydrogels, has appointed Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs. This strategic hire aims to bolster the companys regulatory and clinical capabilities as it prepares for a clinical trial of its PL-14 product in 2025. Dr. Meir brings extensive experience in regulatory strategy and clinical affairs, having worked in leadership roles at MedTech SME Ltd., Keystone Heart, and Alma Lasers. Her appointment underscores Polyrizons commitment to maintaining high standards of regulatory compliance and clinical excellence. The companys innovative hydrogel technology, designed to act as a biological mask against viruses and allergens, is central to its mission of delivering cutting-edge solutions.
Management Changes
growth-positive
Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs
Polyrizon Ltd., a biotech company specializing in innovative intranasal hydrogels, announced the appointment of Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs. This strategic hire is part of Polyrizons preparations for its upcoming clinical trial for PL-14, expected to commence in 2025. Dr. Meir brings extensive experience in regulatory strategy and clinical affairs, having held leadership roles in various medical device and pharmaceutical companies. Her appointment is seen as a move to strengthen Polyrizons capabilities in achieving successful product development and regulatory approval. The companys proprietary hydrogel technology aims to provide a barrier against viruses and allergens, with further development focused on nasal delivery of active pharmaceutical ingredients.
Management Changes
growth-positive
Polyrizon's Moving Forward with Expected 2025 Clinical Trial - Entered Manufacturing Agreement for its PL-14 Allergy Blocker
Polyrizon Ltd., a biotech company specializing in intranasal hydrogels, has entered into a manufacturing agreement with Eurofins CDMO Amatsiaquitaine S.A.S, a European GMP manufacturer. This partnership will provide Clinical Trial Material for Polyrizons PL-14 allergy blocker, which is set for a clinical trial in 2025. The collaboration ensures a reliable manufacturing source, supporting Polyrizons efforts to commercialize its innovative allergy protection solutions. The agreement marks a significant milestone for Polyrizon, aligning with its mission to address allergy-related health issues through unique nasal sprays. The manufacturing site will adhere to USA and European regulatory standards, supporting the companys clinical trial needs.
Partners
growth-positive
Polyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance
Polyrizon Ltd., a development stage biotech company, has appointed Asaf Azulay as its new VP of Regulatory Affairs and Quality Assurance. This strategic move underscores Polyrizons commitment to maintaining high industry standards as it advances its innovative intranasal hydrogel solutions. Asaf Azulay brings over 20 years of experience in the medical devices industry, which will be crucial in navigating complex regulatory environments and ensuring compliance with international standards. This appointment is expected to enhance Polyrizons ability to bring breakthrough therapies to market, supporting its mission to deliver safe and effective solutions. The companys proprietary hydrogel technology aims to provide a barrier against viruses and allergens, with further developments in drug delivery underway.
Management Changes
growth-positive
Polyrizon Enters into GMP Manufacturing Agreement for CTM Supply of its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial
Polyrizon Ltd., a biotech company specializing in intranasal hydrogels, has signed a manufacturing agreement with Eurofins CDMO Amatsiaquitaine S.A.S, a European GMP manufacturer. This partnership will provide Clinical Trial Material for Polyrizons PL-14 allergy blocker, preparing for a clinical trial in 2025. The collaboration ensures a reliable manufacturing source, aligning with USA and European regulatory standards. Polyrizons innovative technology aims to offer effective allergy protection through nasal sprays, marking a significant milestone in their mission to address allergy-related health issues.
Partners
growth-positive
Polyrizon Partners with Eurofins for Clinical Trial Manufacturing of PL-14 Allergy Blocker
Polyrizon, a biotech company specializing in intranasal hydrogels, has entered into a manufacturing agreement with Eurofins CDMO Amatsiaquitaine S.A.S, a European-based GMP manufacturer. This partnership aims to produce Clinical Trial Material for Polyrizons PL-14 allergy blocker, in preparation for a clinical trial scheduled for 2025. The collaboration provides Polyrizon with access to large-scale commercial production capabilities and compliance with USA and European regulatory standards. This agreement marks a significant milestone in Polyrizons development program, positioning the company for future commercialization efforts. The clinical trial will evaluate the safety and efficacy of PL-14 as an allergy blocker, advancing Polyrizons mission to address allergy-related health issues.
Partners
growth-positive
Polyrizon Announces Closing of $4.2 Million Initial Public Offering
Polyrizon Ltd., a biotech company specializing in innovative medical device hydrogels, announced the closing of its initial public offering (IPO) on October 30, 2024. The company offered 958,903 units at $4.38 per unit, raising gross proceeds of $4.2 million. Each unit includes one ordinary share and three warrants. Aegis Capital Corp. acted as the sole book-running manager for the offering, with the potential to increase proceeds to approximately $4.82 million if an overallotment option is exercised. The funds will be used for preclinical and clinical development, research, debt repayment, and potential future acquisitions. The IPO marks a significant step for Polyrizon as it seeks to advance its hydrogel technology for nasal sprays.
Public Trading
growth-positive
Aegis Capital Corp. Acted as Sole Bookrunner on a $4.2 Million (IPO) Initial Public Offering for Polyrizon Ltd. (NASDAQ: PLRZ)
Polyrizon Ltd., a biotech company specializing in innovative medical device hydrogels, has successfully completed a $4.2 million Initial Public Offering (IPO) with Aegis Capital Corp. acting as the sole bookrunner. Polyrizons technology, including the Capture and Contain (C&C) hydrogel, is designed to provide a barrier against viruses and allergens. The company is also developing the Trap and Target (T&T) technology for nasal delivery of active pharmaceutical ingredients. This IPO marks a significant step in Polyrizons growth, providing capital to further develop their proprietary technologies.
Public Trading
growth-positive
Polyrizon Announces Pricing of $4.2 Million Initial Public Offering and Listing on the Nasdaq Capital Market Under New Ticker “PLRZ”
Polyrizon, a biotech company specializing in medical device hydrogels, announced the pricing of its initial public offering (IPO) on the Nasdaq Capital Market under the symbol PLRZ. The company is offering 958,903 units at $4.38 per unit, aiming to raise $4.2 million in gross proceeds, potentially reaching $4.82 million if the underwriters over-allotment option is exercised. The proceeds will be used for preclinical and clinical development, research, debt repayment, working capital, and potential acquisitions. Trading is expected to begin on October 29, 2024. The IPO represents a significant milestone for Polyrizon, providing increased visibility and liquidity, though it may lead to shareholder dilution.
Public Trading
growth-positive
Polyrizon pays $3M for license to SciSparc's preclinical cannabinoid pain therapy
Israeli biotech company SciSparc has entered into a licensing agreement with its partner Polyrizon for its cannabinoid receptor type 2 (CB2R) agonist, SCI-160, aimed at developing pain therapies. Polyrizon will receive an exclusive, royalty-bearing global license for SCI-160, a synthetic combination of cannabinoids and N-acylethanolamines. In exchange, SciSparc will receive $3 million in Polyrizon shares and potentially another $3 million in cash milestone payments, along with royalties. The agreement allows SciSparc to benefit financially without further investment in development. SCI-160 has shown promising results in preclinical studies, offering analgesic effects comparable to high-dose morphine without significant side effects. The partnership, initiated in May 2022, combines SciSparcs platform with Polyrizons drug delivery technology.
Partners
growth-positive
Medigus: Polyrizon Signed an Agreement with Nurexone for Intranasal Administration of Cutting - Edge Therapy for Spinal Cord Injuries
Medigus Ltd announced that Polyrizon Ltd, in which Medigus owns a stake, has signed a collaboration agreement with NurExone Biologic Inc. Under the agreement, Polyrizon will use its advanced Trap and Target platform to develop an intranasal delivery system for NurExones ExoTherapy for patients with traumatic spinal cord injuries. NurExone will cover the costs of formulation development and pay development fees to Polyrizon. Polyrizon may also assist NurExone with regulatory submissions. The collaboration gives NurExone exclusive manufacturing and marketing rights for the formulations. The agreement is expected to have a positive impact on Medigus Ltds growth.
Partners
growth-positive
Medigus: Polyrizon to Test its Product Candidate for Protection Against the Highly Transmissible Corona Virus Omicron Variant
Medigus Ltd announced that Polyrizon Ltd, a company in which Medigus owns 35.86% of its share capital, will evaluate the viral infection prophylaxis effect of its product candidate against the Omicron variant of the coronavirus. Polyrizons product has shown potential in preventing human coronavirus 229E and influenza virus infection. The study will be conducted in collaboration with Prof. Fabio Sonvico from the Department of Food and Drug Science of Parma University, Italy. The aim is to assess the protection effect of Polyrizons Capture and Contain (C&C™) platform against the Omicron variant. The study is planned to begin in Q1 2022. Polyrizons C&C™ platform is a prevention-focused approach that, when combined with vaccination and other preventive measures, aims to reduce the risk of infection. Medigus Ltd is a technology company focused on advanced medical solutions, digital commerce, and electric vehicle markets.
PartnersInvestment
growth-positive
Medigus: Polyrizon Innovative Technology Demonstrated it may Prevent Allergic Reaction Caused by Common Allergens
Medigus Ltd announced that Polyrizon Ltds pre-clinical data demonstrated a potential to prevent allergic reactions caused by house dust mites and pollen allergens. Polyrizons innovative product, PL-14, has the potential to reduce the inflammatory response and prevent the interaction of allergens with host cells. The product is designed to protect the nasal cavity and respiratory tract by creating a physical barrier. Recent studies also showed the products effectiveness against respiratory viruses. The first efficacy results are expected within the next 12 months.
PartnersInvestment
growth-positive
Medigus: Polyrizon to Initiate Processes Towards FDA Submission
Medigus Ltd announced that Polyrizon Ltd has engaged with a Contract Research Organization (CRO) to advise the company in its pursuit of FDA submission for its coronavirus and allergen preventative products. Polyrizon specializes in the development of innovative nasal gels to provide preventative treatment against viruses, including COVID-19 and influenza. The CRO will work with Polyrizon on a readiness plan for FDA submission. Polyrizon recently submitted a patent application for its products. Medigus Ltd is a technology company focused on advanced medical solutions, digital commerce, and electric vehicle markets.
Partners
https://newsonlineche.in/2021/07/23/polyrizons-innovative-proprietary-technology-found-effective-against-coronavirus-in-a-pre-clinical-study/
growth-positive
Medigus to Invest up to an Additional $150,000 in COVID-19 Protection Biogel Developer Polyrizon
Medigus Ltd. has announced a non-binding term sheet for an investment in Polyrizon Ltd., a company developing biological gels for protecting patients against biological threats. Medigus currently holds 19.9% in Polyrizon and will own approximately 33% of the company on a fully diluted basis after the additional investment of $100,000. Medigus and other Polyrizon shareholders have the option to invest an additional aggregate amount of up to $50,000. Medigus has an exclusive license to resell Polyrizons products, including a unique Biogel for protection against COVID-19, once FDA approval is received. Polyrizon develops biological gels to protect against biological threats and external pathogens.
Investment
growth-negative
Insight Weekly: Banks' efficiency push;vacuuming carbon;Big Pharma diversity goals
The article discusses the impact of the digital revolution on the U.S. banking and financial technology landscape, highlighting the potential for job cuts in the industry. It also mentions the repeal of the true lender federal banking rule, which could embolden state banking regulators to scrutinize bank-fintech partnerships. The article also touches on the need for direct air capture technology to combat climate change and the push for greater diversity in biopharmaceutical companies. The date of the event described in the article is not provided.
Layoffs
Polyrizon Team
Employee Info
| Employees (range) | 1-10 |
| Exact count | 8 |
| Team members | 4 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 11 classification IDs that could be used for matching.
Polyrizon Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 90/100 |
| Missing | markets, not claimed |
| BI Verification | Natalia Golczar |
| Registrar ID | 513637025 |
| Phone | +972993740333|0533351978 |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2023-11-24T00:00:00.000Z |
| Created | 2015-01-04T00:00:00.000Z |
| Claimed | Yes |
| Status detail | Public on NASDAQ on Oct, 2024; |